Agency Flags Compounding Pharmacy for Bulk Production of GLP-1 Mimics
The FDA issued a warning letter to Empower Pharmacy for mass-producing compounded semaglutide and tirzepatide that are essentially copies of approved drugs, violating Section 503A of the Federal Food, Drug, and Cosmetic Act. Inspectors also found that sterile drug products were prepared under insanitary conditions, with deficiencies in airflow testing, media fills, and environmental monitoring. The pharmacy has 15 working days to respond to the agency's findings.
The FDA's November 2025 inspection of Empower Pharmacy revealed large-scale production of compounded semaglutide and tirzepatide combined with B vitamins, which the agency viewed as a thin justification for copying approved drugs. Under Section 503A, compounding must serve documented individual patient needs, and the agency determined that Empower's output volume undermined that rationale, reclassifying the products as unapproved new drugs.
Sterility deficiencies were also cited, including inadequate dynamic smoke studies in clean rooms, media fills that did not properly challenge aseptic methods, and weak environmental monitoring and equipment oversight. The agency noted that some corrective actions were acceptable while others fell short, and Empower now faces a 15-working-day deadline to address the findings.
This action could tighten the GLP-1 compounding market, which expanded rapidly during shortages that have since ended. Patients who turned to compounded versions for affordability or supply reasons may face reduced access, potentially disrupting ongoing treatment or pushing them toward higher-cost brand-name drugs. Other compounding pharmacies may also face heightened scrutiny, which could reshape prescribing practices and patient options nationwide.